(Total Views: 774)
Posted On: 11/03/2021 7:06:16 AM
Post# of 153988
Re: KenChowder #109585
(rolls pedestal into the room, climbs on top)
(cracks knuckles)
OK, here we go. Icon time.
"75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS reported by the Company on August 25, 2021."
75% of patients saw a 3,600% increase in overall survival. That survival increase was regardless of if they saw lower circulating tumor cells or not. Apparently 86% of the group did see lowered CTCs while 14% at baseline did not see improvement in that marker.
(checks notes, rereads the press release)
(scratches head)
Actually, it may be that at baseline (of the 75% of patients showing this 3,600% increase in OS) there were 14% of the patients who already had low circulating tumor cells while 86% of the patients in the trial saw their baseline CTCs lower after taking Leronlimab. But regardless, 75% of all patients in the trial saw in increase of 3,600% in overall survival.
(looks again at the press release)
(meanders out of the room lost in thought)
(cracks knuckles)
OK, here we go. Icon time.
"75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS reported by the Company on August 25, 2021."
75% of patients saw a 3,600% increase in overall survival. That survival increase was regardless of if they saw lower circulating tumor cells or not. Apparently 86% of the group did see lowered CTCs while 14% at baseline did not see improvement in that marker.
(checks notes, rereads the press release)
(scratches head)
Actually, it may be that at baseline (of the 75% of patients showing this 3,600% increase in OS) there were 14% of the patients who already had low circulating tumor cells while 86% of the patients in the trial saw their baseline CTCs lower after taking Leronlimab. But regardless, 75% of all patients in the trial saw in increase of 3,600% in overall survival.
(looks again at the press release)
(meanders out of the room lost in thought)
(14)
(0)
